Inclusion of people with multiple long-term conditions in pregnancy research: patient, public and stakeholder involvement and engagement in a randomised controlled trial.
Maternity research
Multiple long-term conditions
PPIE
Patient and public involvement and engagement
Pregnancy
Stakeholder engagement
Journal
Research involvement and engagement
ISSN: 2056-7529
Titre abrégé: Res Involv Engagem
Pays: England
ID NLM: 101708164
Informations de publication
Date de publication:
07 Oct 2024
07 Oct 2024
Historique:
received:
07
05
2024
accepted:
10
09
2024
medline:
8
10
2024
pubmed:
8
10
2024
entrez:
7
10
2024
Statut:
epublish
Résumé
Both pregnant women and those with multiple long-term conditions are under-served groups in clinical research. Informing and improving research through patient and public involvement, including pregnant women with two or more long-term health conditions, is critical to increasing their inclusion in maternity research. Giant PANDA is a randomised controlled trial, evaluating the effect of a treatment initiation strategy with nifedipine versus labetalol on severe maternal hypertension and a composite outcome of fetal/neonatal death, or neonatal unit admission. We aimed to undertake a mixed methods study-within-a-project within the Giant PANDA trial to understand barriers and facilitators to participation, understand and optimise current representativeness of clinical trial delivery of those with multiple long-term conditions and co-create a checklist to support their inclusion in pregnancy research. We undertook online workshops with women with lived experience and hybrid workshops with healthcare professionals who look after women with multiple long-term conditions. A site audit of Giant PANDA sites provided insights into research delivery capacity and health system set-up, and how this influences inclusion. An extension to the Giant PANDA screening log captured data on multiple long-term conditions enabling analysis of the impact of these health conditions on women's inclusion in the trial. We co-created a checklist of recommendations for those designing and recruiting to similar clinical trials. Five key recommendations were identified including a need to (1) involve women with multiple long-term conditions as partners in maternity research and (2) minimise barriers that stop them from taking part through (3) designing and delivering research that is flexible in time and place (4) consider research as part of care for everyone, including those with multiple long-term conditions and (5) measure and report inclusion of those with two or more health conditions in maternity research. Multiple long-term conditions were not a barrier to recruitment or randomisation in the Giant PANDA trial. Women with multiple long-term conditions would like opportunities to find out about and participate in research which accounts for their needs. Our checklist aims to support those designing and delivering maternity research to optimise inclusion of individuals with multiple-long term conditions. Giant PANDA: EudraCT number: 2020-003410-12, ISRCTN: 12,792,616. Pregnant women with two or more long-term health problems may be less likely to be included in research. Including them in research is important to ensure we give the best care. Giant PANDA is a study comparing two medicines (nifedipine or labetalol) to manage high blood pressure in pregnancy. As part of the study, we looked at the number of women with two or more long-term health conditions included. We talked to women with experience of two or more long-term health conditions in pregnancy, and healthcare staff who look after these women. Finally, we looked at how maternity research is set up in Giant PANDA study sites. We found that women with two or more health conditions were taking part in the Giant PANDA study. Women with two or more long-term conditions would like the choice to be included in research which considers their needs. This includes being involved in the planning and ongoing support for studies. Research needs to be part of routine care, flexible, and not time consuming to help those with two or more health conditions take part. Our findings have been used to make a checklist to help plan and support studies for women and birthing people with two or more long-term health conditions.
Sections du résumé
BACKGROUND
BACKGROUND
Both pregnant women and those with multiple long-term conditions are under-served groups in clinical research. Informing and improving research through patient and public involvement, including pregnant women with two or more long-term health conditions, is critical to increasing their inclusion in maternity research. Giant PANDA is a randomised controlled trial, evaluating the effect of a treatment initiation strategy with nifedipine versus labetalol on severe maternal hypertension and a composite outcome of fetal/neonatal death, or neonatal unit admission. We aimed to undertake a mixed methods study-within-a-project within the Giant PANDA trial to understand barriers and facilitators to participation, understand and optimise current representativeness of clinical trial delivery of those with multiple long-term conditions and co-create a checklist to support their inclusion in pregnancy research.
METHODS
METHODS
We undertook online workshops with women with lived experience and hybrid workshops with healthcare professionals who look after women with multiple long-term conditions. A site audit of Giant PANDA sites provided insights into research delivery capacity and health system set-up, and how this influences inclusion. An extension to the Giant PANDA screening log captured data on multiple long-term conditions enabling analysis of the impact of these health conditions on women's inclusion in the trial. We co-created a checklist of recommendations for those designing and recruiting to similar clinical trials.
RESULTS
RESULTS
Five key recommendations were identified including a need to (1) involve women with multiple long-term conditions as partners in maternity research and (2) minimise barriers that stop them from taking part through (3) designing and delivering research that is flexible in time and place (4) consider research as part of care for everyone, including those with multiple long-term conditions and (5) measure and report inclusion of those with two or more health conditions in maternity research. Multiple long-term conditions were not a barrier to recruitment or randomisation in the Giant PANDA trial.
CONCLUSION
CONCLUSIONS
Women with multiple long-term conditions would like opportunities to find out about and participate in research which accounts for their needs. Our checklist aims to support those designing and delivering maternity research to optimise inclusion of individuals with multiple-long term conditions.
TRIAL REGISTRATION
BACKGROUND
Giant PANDA: EudraCT number: 2020-003410-12, ISRCTN: 12,792,616.
Pregnant women with two or more long-term health problems may be less likely to be included in research. Including them in research is important to ensure we give the best care. Giant PANDA is a study comparing two medicines (nifedipine or labetalol) to manage high blood pressure in pregnancy. As part of the study, we looked at the number of women with two or more long-term health conditions included. We talked to women with experience of two or more long-term health conditions in pregnancy, and healthcare staff who look after these women. Finally, we looked at how maternity research is set up in Giant PANDA study sites. We found that women with two or more health conditions were taking part in the Giant PANDA study. Women with two or more long-term conditions would like the choice to be included in research which considers their needs. This includes being involved in the planning and ongoing support for studies. Research needs to be part of routine care, flexible, and not time consuming to help those with two or more health conditions take part. Our findings have been used to make a checklist to help plan and support studies for women and birthing people with two or more long-term health conditions.
Autres résumés
Type: plain-language-summary
(eng)
Pregnant women with two or more long-term health problems may be less likely to be included in research. Including them in research is important to ensure we give the best care. Giant PANDA is a study comparing two medicines (nifedipine or labetalol) to manage high blood pressure in pregnancy. As part of the study, we looked at the number of women with two or more long-term health conditions included. We talked to women with experience of two or more long-term health conditions in pregnancy, and healthcare staff who look after these women. Finally, we looked at how maternity research is set up in Giant PANDA study sites. We found that women with two or more health conditions were taking part in the Giant PANDA study. Women with two or more long-term conditions would like the choice to be included in research which considers their needs. This includes being involved in the planning and ongoing support for studies. Research needs to be part of routine care, flexible, and not time consuming to help those with two or more health conditions take part. Our findings have been used to make a checklist to help plan and support studies for women and birthing people with two or more long-term health conditions.
Identifiants
pubmed: 39375814
doi: 10.1186/s40900-024-00634-7
pii: 10.1186/s40900-024-00634-7
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101Subventions
Organisme : Health Technology Assessment Programme
ID : NIHR128721
Informations de copyright
© 2024. The Author(s).
Références
Whitty CJMMC, Goddard A, Alderson D, Marshall M, Calderwood C, Atherton F, McBride M, Atherton J, Stokes-Lampard H, Reid W, Powis S, Marx C. Rising to the challenge of multimorbidity. BMJ. 2020. https://doi.org/10.1136/bmj.l6964 .
doi: 10.1136/bmj.l6964
pubmed: 31907164
pmcid: 7190283
Brown HK, Fung K, Cohen E, Dennis CL, Grandi SM, Rosella LC, et al. Patterns of multiple chronic conditions in pregnancy: population-based study using latent class analysis. Paediatr Perinat Epidemiol. 2023. https://doi.org/10.1111/ppe.13016 .
doi: 10.1111/ppe.13016
pubmed: 37864500
pmcid: 10946523
Smith DD, Pippen JL, Adesomo AA, Rood KM, Landon MB, Costantine MM. Exclusion of pregnant women from clinical trials during the coronavirus disease 2019 pandemic: a review of international registries. Am J Perinatol. 2020;37(8):792–9.
doi: 10.1055/s-0040-1712103
pubmed: 32428965
pmcid: 7356075
Lee SI, Azcoaga-Lorenzo A, Agrawal U, Kennedy JI, Fagbamigbe AF, Hope H, Subramanian A, Anand A, Taylor B, Nelson-Piercy C, Damase-Michel C. Epidemiology of pre-existing multimorbidity in pregnant women in the UK in 2018: a population-based cross-sectional study. BMC Pregnancy Childbirth. 2022;22(1):1–15.
doi: 10.1186/s12884-022-04442-3
Brown HK, McKnight A, Aker A. Association between pre-pregnancy multimorbidity and adverse maternal outcomes: a systematic review. J Multimorb Comorbidity. 2022;12:26335565221096584.
doi: 10.1177/26335565221096584
Knight MBK, Tuffnell D, Shakespeare J, Kotnis R, Kenyon S, Kurinczuk JJ (Eds.) on behalf of MBRRACE-UK,. Saving Lives, Improving Mothers’ Care - Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2016–18. Oxford: National Perinatal Epidemiology Unit, University of Oxford 2020. Contract No.: 25/05/2023.
Frise CRS, Kelly T, Shakespeare J, Cranfield K, Mathers R, Bunch K, Knight M on behalf of the MBRRACE-UK diabetes and multimorbidity chapter-writing group. Messages on caring for women with multiple morbidities. Oxford: National Perinatal Epidemiology Unit, University of Oxford 2022. In Knight M, Bunch K, Patel R, Shakespeare J, Kotnis R, Kenyon S, Kurinczuk JJ (Eds.) on behalf of MBRRACE-UK.Saving Lives, Improving Mothers’ Care Core Report - Lessons learned to inform maternity care from the UK andIreland Confidential Enquiries into Maternal Deaths and Morbidity 2018-20. Oxford: National Perinatal EpidemiologyUnit, University of Oxford 2022: p17-20
Knight MBK, Felker A, Patel R, Kotnis R, Kenyon S, Kurinczuk JJ (Eds.) on behalf of MBRRACE-UK. Saving Lives, Improving Mothers’ Care Core Report - Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2019–21. Oxford: National Perinatal Epidemiology Unit, University of Oxford 2023.
National Institute for Health and Care Research. Improving inclusion of under-served groups in clinical research: Guidance from the NIHR-INCLUDE project. UK2020. https://www.nihr.ac.uk/documents/improving-inclusion-of-under-served-groups-in-clinical-research-guidance-from-include-project/25435#citations .
Department of Health and Social Care. Women’s Health Strategy for England; 2022. Women's Health Strategy for England - GOV.UK (www.gov.uk)
Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:1–14.
doi: 10.1186/s13063-015-1023-4
Bonell C, Oakley A, Hargreaves J, Strange V, Rees R. Assessment of generalisability in trials of health interventions: suggested framework and systematic review. BMJ. 2006;333(7563):346–9.
doi: 10.1136/bmj.333.7563.346
pubmed: 16902217
pmcid: 1539056
National Institute for Health and Care Research. Payment guidance for researchers and professionals 2023. https://www.nihr.ac.uk/documents/payment-guidance-for-researchers-and-professionals/27392 . Accessed 08 Dec 2023.
Guy S, Inglis A. Tips for trainers: introducing the ‘H’form—a method for monitoring and evaluation. PLA Notes. 1999;34:84–7.
ESRC STEPS (Social, Technological and Environmental Pathways to Sustainability. METHODS VIGNETTES: EVALUATION H 2016. https://steps-centre.org/pathways-methods-vignettes/methods-vignettes-evaluation-h/ .
(td-net) Social, Technological and Environmental Pathways to Sustainability. Methods and tools for co-producing knowledge: Method Factsheets for td-research: Evaluation H. https://naturalsciences.ch/co-producing-knowledge-explained/methods/method_factsheets/evaluation_h .
MuM-PreDiCT. MuM-PreDiCT list of conditions 2022. https://drive.google.com/file/d/1Q3LTzcXGnEFcS6eMAA0pntEUUUa-iTtp/view .
Lee SI, Hanley S, Vowles Z, Plachcinski R, Moss N, Singh M, et al. The development of a core outcome set for studies of pregnant women with multimorbidity. BMC Med. 2023;21(1):314.
doi: 10.1186/s12916-023-03013-3
pubmed: 37605204
pmcid: 10441728
Kars MC, van Thiel GJ, van der Graaf R, Moors M, de Graeff A, van Delden JJ. A systematic review of reasons for gatekeeping in palliative care research. Palliat Med. 2016;30(6):533–48.
doi: 10.1177/0269216315616759
pubmed: 26577927
Beeson JG, Homer CS, Morgan C, Menendez C. Multiple morbidities in pregnancy: time for research, innovation, and action. PLoS Med. 2018;15(9):e1002665.
doi: 10.1371/journal.pmed.1002665
pubmed: 30252846
pmcid: 6155445
Chappell LC, Brocklehurst P, Green ME, Hunter R, Hardy P, Juszczak E, et al. Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial. The Lancet. 2019;394(10204):1181–90.
doi: 10.1016/S0140-6736(19)31963-4
Thangaratinam S, Marlin N, Newton S, Weckesser A, Bagary M, Greenhill L, et al. AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies. Health Technol Assess. 2018;22(23):1–152.
doi: 10.3310/hta22230
pubmed: 29737274
pmcid: 5960819
Feig DS, Donovan LE, Zinman B, Sanchez JJ, Asztalos E, Ryan EA, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2020;8(10):834–44.
doi: 10.1016/S2213-8587(20)30310-7
pubmed: 32946820
Knudsen SDP, Roland CB, Alomairah SA, Jessen AD, Molsted S, Clausen TD, et al. Physical activity in pregnancy: a mixed methods process evaluation of the FitMum randomised controlled trial interventions. BMC Public Health. 2022;22(1):2283.
doi: 10.1186/s12889-022-14717-1
pubmed: 36474181
pmcid: 9724308
Cooper S, Lewis S, Thornton JG, Marlow N, Watts K, Britton J, et al. The SNAP trial: a randomised placebo-controlled trial of nicotine replacement therapy in pregnancy–clinical effectiveness and safety until 2 years after delivery, with economic evaluation. Health Technol Assess. 2014;18(54):1.
doi: 10.3310/hta18540
pubmed: 25405576
pmcid: 4781176
National Institute for Health and Care Research. Best Research for Best Health: The Next Chapter. Our operational priorities. In: Care DoHaS, editor. 2021. Best Research for Best Health: The Next Chapter | NIHR
Owen N, Dew L, Logan S, Denegri S, Chappell LC. Research policy for people with multiple long-term conditions and their carers. J Multimorb Comorbidity. 2022;12:26335565221104410.
doi: 10.1177/26335565221104407
National Institute for Health and Care Research. Embedding a research culture 2023. https://www.nihr.ac.uk/health-and-care-professionals/engagement-and-participation-in-research/embedding-a-research-culture.htm .
Royal College of Physicians and National Institute for Health and Care Research. RCP NIHR position statement: making research everybody’s business; 2022.
Washington V, Franklin JB, Huang ES, Mega JL, Abernethy AP. Diversity, equity, and inclusion in clinical research: a path toward precision health for everyone. Clin Pharmacol Ther. 2023;113(3):575–84.
doi: 10.1002/cpt.2804
pubmed: 36423203
National Institute for Health and Care Research. Ensuring that COVID-19 Research is Inclusive: Guidance from the NIHR CRN INCLUDE project 2020. https://www.nihr.ac.uk/documents/ensuring-that-covid-19-research-is-inclusive-guidance-from-the-nihr-crn-include-project/32647 .
National Institute for Health and Care Research. NIHR Race Equality Framework 2022. https://www.nihr.ac.uk/documents/nihr-race-equality-framework/30388?pr= .
National Institute for Health and Care Research Applied Research Collaboration East Midlands. EQUALITY IMPACT ASSESSMENT (EqIA) TOOLKIT; 2021.
Ashworth D, Battersby C, Bick D, Green M, Hardy P, Leighton L, et al. A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA). Trials. 2023;24(1):584.
doi: 10.1186/s13063-023-07582-9
pubmed: 37700365
pmcid: 10496358
National Institute for Health and Care Research. Multiple long-term conditions - Studies within a project (SWAP) 2021 [updated March 2023. 1.2. https://www.nihr.ac.uk/documents/multiple-long-term-conditions-studies-within-a-project-swap/27818 .
Health Research Authority and National Institute for Health and Care Research INVOLVE. Public involvement in research and research ethics committee review 2016. https://www.invo.org.uk/posttypepublication/public-involvement-in-research-and-research-ethics-committee-review/ .
Health Research Authority. UK Policy Framework for Health and Social Care Research 2023. https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/uk-policy-framework-health-social-care-research/ .
National Institiute for Health and Care Research. Briefing notes for researchers—public involvement in NHS, health and social care research 2021. https://www.nihr.ac.uk/documents/briefing-notes-for-researchers-public-involvement-in-nhs-health-and-social-care-research/27371 .
Staniszewska S, Brett J, Simera I, Seers K, Mockford C, Goodlad S, et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. Res Involve Engag. 2017;3(1):13.
doi: 10.1186/s40900-017-0062-2